Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720Maria R. Baer, Richard A. Larson, Michael A. Caligiuri et al.|Journal of Clinical Oncology|2008Cited by 131